Pekka MÃ¤nnistÃ¶

List of Publications by Year
in descending order

323 papers	10,566 citations	38742 50 h-index	56724 83 g-index
328 all docs	328 docs citations	328 times ranked	9500 citing authors

#	Article	IF	Citations
1	Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacological Reviews, 1999, 51, 593-628.	16.0	752
2	Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 3513-3518.	7.1	335
3	Pharmacologically Diverse Antidepressants Rapidly Activate Brain-Derived Neurotrophic Factor Receptor TrkB and Induce Phospholipase-CÎ³ Signaling Pathways in Mouse Brain. Neuropsychopharmacology, 2007, 32, 2152-2162.	5.4	277
4	Site-Specific Role of Catechol-O-Methyltransferase in Dopamine Overflow within Prefrontal Cortex and Dorsal Striatum. Journal of Neuroscience, 2007, 27, 10196-10209.	3.6	244
5	On the role of prolyl oligopeptidase in health and disease. Neuropeptides, 2007, 41, 1-24.	2.2	210
6	Brain catecholamine metabolism in catecholâ€Oâ€methyltransferase (COMT)â€deficient mice. European Journal of Neuroscience, 2002, 15, 246-256.	2.6	166
7	Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice. Journal of Neurochemistry, 2010, 114, 1745-1755.	3.9	149
8	Characteristics of catechol O-methyltransferase (COMT) and properties of selective COMT inhibitors. , 1992, 39, 291-350.		149
9	Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors. Journal of Medicinal Chemistry, 1989, 32, 841-846.	6.4	139
10	Catechol-O-methyltransferase gene polymorphism and chronic human pain. Pharmacogenetics and Genomics, 2012, 22, 673-691.	1.5	134
11	Rationale for Selective COMT Inhibitors as Adjuncts in the Drug Treatment of Parkinson's Disease. Basic and Clinical Pharmacology and Toxicology, 1990, 66, 317-323.	0.0	127
12	The multiple faces of quercetin in neuroprotection. Expert Opinion on Drug Safety, 2009, 8, 397-409.	2.4	126
13	7-Nitroindazole, a nitric oxide synthase inhibitor, has anxiolytic-like properties in exploratory models of anxiety. Psychopharmacology, 1997, 131, 399-405.	3.1	125
14	Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. Experimental Neurology, 2011, 228, 99-108.	4.1	118
15	General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. General Pharmacology, 1994, 25, 813-824.	0.7	114
16	New selective COMT inhibitors: useful adjuncts for Parkinson's disease?. Trends in Pharmacological Sciences, 1989, 10, 54-56.	8.7	109
17	Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat. European Journal of Pharmacology, 1988, 153, 263-269.	3.5	107
18	Prolyl Oligopeptidase: A Potential Target for the Treatment of Cognitive Disorders. Drug News and Perspectives, 2007, 20, 293.	1.5	98

#	Article	IF	Citations
19	Activation of 5-HT2A receptors impairs response control of rats in a five-choice serial reaction time task. Neuropharmacology, 2000, 39, 471-481.	4.1	97
20	A prolyl oligopeptidase inhibitor, KYPâ€2047, reduces Î±â€synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease. British Journal of Pharmacology, 2012, 166, 1097-1113.	5.4	94
21	Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human Î±-synuclein. Neurobiology of Disease, 2005, 20, 303-313.	4.4	93
22	Distribution of catecholâ€Oâ€methyltransferase (COMT) proteins and enzymatic activities in wildâ€type and soluble COMT deficient mice. Journal of Neurochemistry, 2010, 113, 1632-1643.	3.9	87
23	Different in vivo properties of three new inhibitors of catechol Oâ€methyltransferase in the rat. British Journal of Pharmacology, 1992, 105, 569-574.	5.4	86
24	Amantadine protects dopamine neurons by a dual action: Reducing activation of microglia and inducing expression of GNDF in astroglia. Neuropharmacology, 2011, 61, 574-582.	4.1	84
25	Impairing effect of food on ketoconazole absorption. Antimicrobial Agents and Chemotherapy, 1982, 21, 730-733.	3.2	82
26	Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route. Antimicrobial Agents and Chemotherapy, 1983, 23, 721-725.	3.2	82
27	Target tissue morphology and serum biochemistry following 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) exposure in a TCDD-susceptible and a TCDD-resistant rat strain*1. Fundamental and Applied Toxicology, 1989, 12, 698-712.	1.8	82
28	Neurotransmitter control of thyrotropin secretion in the rat. European Journal of Pharmacology, 1975, 30, 221-229.	3.5	79
29	Effect of Dopamine Uptake Inhibition on Brain Catecholamine Levels and Locomotion in Catechol-O-methyltransferase-Disrupted Mice. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 1309-1316.	2.5	79
30	Evolutionary relationships of the prolyl oligopeptidase family enzymes. FEBS Journal, 2004, 271, 2705-2715.	0.2	79
31	Inhibition of nitric oxide synthase causes anxiolytic-like behaviour in an elevated plus-maze. NeuroReport, 1995, 6, 1413-1416.	1.2	77
32	The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse. Neurobiology of Disease, 2014, 68, 1-15.	4.4	75
33	Gene therapy with <scp>AAV</scp>2â€<scp>CDNF</scp> provides functional benefits in a rat model of <scp>P</scp>arkinson's disease. Brain and Behavior, 2013, 3, 75-88.	2.2	72
34	Catechol 0-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats. Behavioural Brain Research, 1997, 82, 195-202.	2.2	64
35	A Cyclopent-2-enecarbonyl Group Mimics Proline at the P2 Position of Prolyl Oligopeptidase Inhibitors. Journal of Medicinal Chemistry, 2004, 47, 5605-5607.	6.4	62
36	Improved assay of reaction products to quantitate catechol-O-methyltransferase activity by high-performance liquid chromatography with electrochemical detection. Biomedical Applications, 1995, 663, 137-142.	1.7	60

#	Article	IF	Citations
37	Modulation of histamine H3receptors in the brain of 6-hydroxydopamine-lesioned rats. European Journal of Neuroscience, 2000, 12, 3823-3832.	2.6	60
38	Issues About the Physiological Functions of Prolyl Oligopeptidase Based on Its Discordant Spatial Association With Substrates and Inconsistencies Among mRNA, Protein Levels, and Enzymatic Activity. Journal of Histochemistry and Cytochemistry, 2009, 57, 831-848.	2.5	59
39	Epistasis between polymorphisms in COMT, ESR1, and GCH1 influences COMT enzyme activity and pain. Pain, 2014, 155, 2390-2399.	4.2	59
40	Receptor subtypes Y1 and Y5 mediate neuropeptide Y induced feeding in the guinea-pig. British Journal of Pharmacology, 2002, 135, 2029-2037.	5.4	58
41	Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues. Histochemistry and Cell Biology, 2008, 130, 993-1003.	1.7	58
42	Comparative liver toxicity of various erythromycin derivatives in animals. Journal of Antimicrobial Chemotherapy, 1988, 21, 9-27.	3.0	57
43	Are genetic variants of COMT associated with addiction?. Pharmacogenetics and Genomics, 2010, 20, 717-741.	1.5	57
44	Ondansetron, an antagonist of 5-HT3 receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze. Psychopharmacology, 1993, 110, 213-218.	3.1	56
45	d -Amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice. Psychopharmacology, 2004, 172, 1-10.	3.1	56
46	Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors. Biochemical Pharmacology, 2006, 71, 683-692.	4.4	56
47	Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sciences, 1988, 43, 1465-1471.	4.3	54
48	Synergism in gene delivery by small PEIs and three different nonviral vectors. International Journal of Pharmaceutics, 2004, 270, 175-184.	5.2	54
49	Striatal membrane-bound and soluble catechol-O-methyl-transferase after selective neuronal lesions in the rat. Journal of Neural Transmission, 1987, 69, 221-228.	2.8	53
50	Effect of Entacapone, a COMP Inhibitor, on the Pharmacokinetics and Metabolism of Levodopa After Administration of Controlled-Release Levodopa-Carbidopa in Volunteers. Clinical Neuropharmacology, 1995, 18, 46-57.	0.7	53
51	Over-expression of a human chromosome 22q11.2 segment including TXNRD2, COMT and ARVCF developmentally affects incentive learning and working memory in mice. Human Molecular Genetics, 2009, 18, 3914-3925.	2.9	53
52	Catechol-O-Methyltransferase and Pain. International Review of Neurobiology, 2010, 95, 227-279.	2.0	53
53	Determination of catechol-O-methyltransferase activity by high-performance liquid chromatography with electrochemical detection. Analytical Biochemistry, 1984, 137, 69-73.	2.4	52
54	Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl oligopeptidase and its tight binding inhibition by JTP-4819. Biochemical Pharmacology, 2002, 64, 463-471.	4.4	51

#	Article	IF	Citations
55	Strong preferences of dopamine and <scp>l</scp>â€dopa towards lipid head group: importance of lipid composition and implication for neurotransmitter metabolism. Journal of Neurochemistry, 2012, 122, 681-690.	3.9	51
56	Pharmacokinetics and Pharmacodynamics of Entacapone and Tolcapone after Acute and Repeated Administration: A Comparative Study in the Rat. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 498-506.	2.5	50
57	Distribution of Immunoreactive Prolyl Oligopeptidase in Human and Rat Brain. Neurochemical Research, 2007, 32, 1365-1374.	3.3	50
58	Enzymatic detoxification of gluten by germinating wheat proteases: Implications for new treatment of celiac disease. Annals of Medicine, 2009, 41, 390-400.	3.8	50
59	Prolyl oligopeptidase colocalizes with Î±-synuclein, Î²-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinsonâ€™s and Alzheimerâ€™s diseases. Neuroscience, 2013, 242, 140-150.	2.3	49
60	Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner. British Journal of Pharmacology, 2011, 163, 1666-1678.	5.4	48
61	Cellular and subcellular distribution of rat brain prolyl oligopeptidase and its association with specific neuronal neurotransmitters. Journal of Comparative Neurology, 2008, 507, 1694-1708.	1.6	47
62	Molecular dynamics, crystallography and mutagenesis studies on the substrate gating mechanism of prolyl oligopeptidase. Biochimie, 2012, 94, 1398-1411.	2.6	47
63	Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action. ENeuro, 2017, 4, ENEURO.0117-16.2017.	1.9	47
64	Overflow of noradrenaline and dopamine in frontal cortex after [N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine] (DSP-4) treatment: in vivo microdialysis study in anaesthetized rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 355, 267-272.	3.0	46
65	Different synergistic roles of small polyethylenimine and Dosper in gene delivery. Journal of Controlled Release, 2003, 88, 173-183.	9.9	46
66	The effects of diazepam or diphenhydramine on healthy human subjects. Psychopharmacology, 1971, 21, 202-211.	3.1	43
67	Epithelial transport and deamidation of gliadin peptides: a role for coeliac disease patient immunoglobulin A. Clinical and Experimental Immunology, 2011, 164, 127-136.	2.6	43
68	Are Transglutaminase 2 Inhibitors Able to Reduce Gliadin-Induced Toxicity Related to Celiac Disease? A Proof-of-Concept Study. Journal of Clinical Immunology, 2013, 33, 134-142.	3.8	43
69	Adaptations to iron deficiency: cardiac functional responsiveness to norepinephrine, arterial remodeling, and the effect of beta-blockade on cardiac hypertrophy. BMC Physiology, 2002, 2, 1.	3.6	42
70	Lack of robust protective effect of quercetin in two types of 6-hydroxydopamine-induced parkinsonian models in rats and dopaminergic cell cultures. Brain Research, 2008, 1203, 149-159.	2.2	42
71	Fate of single oral doses of erythromycin acistrate, erythromycin stearate and pelleted erythromycin base analysed by mass-spectrometry in plasma of healthy human volunteers. Journal of Antimicrobial Chemotherapy, 1988, 21, 33-43.	3.0	41
72	Effects of aqueous extracts of Halimeda incrassata (Ellis) Lamouroux and Bryothamnion triquetrum (S.G.Gmelim) Howe on hydrogen peroxide and methyl mercury-induced oxidative stress in GT1-7 mouse hypothalamic immortalized cells. Phytomedicine, 2003, 10, 39-47.	5.3	41

#	Article	IF	Citations
73	Effect of tolcapone, a catechol-O-methyltransferase inhibitor, on striatal dopaminergic transmission during blockade of dopamine uptake. European Journal of Pharmacology, 1999, 370, 125-131.	3.5	40
74	Agonists for neuropeptide Y receptors Y1 and Y5 stimulate different phases of feeding in guinea pigs. British Journal of Pharmacology, 2003, 139, 1433-1440.	5.4	40
75	Transcriptional profiling of C57 and DBA strains of mice in the absence and presence of morphine. BMC Genomics, 2007, 8, 76.	2.8	39
76	Time-dependent protective and harmful effects of quercetin on 6-OHDA-induced toxicity in neuronal SH-SY5Y cells. Toxicology, 2008, 250, 1-8.	4.2	39
77	Mechanism of Action of Prolyl Oligopeptidase (PREP) in Degenerative Brain Diseases: Has Peptidase Activity Only a Modulatory Role on the Interactions of PREP with Proteins?. Frontiers in Aging Neuroscience, 2017, 9, 27.	3.4	38
78	EFFECTS OF METHYLMERCAPTOIMIDAZOLE (MMI), PROPYLTHIOURACIL (PTU), POTASSIUM PERCHLORATE (KClO4) AND POTASSIUM IODIDE (KI) ON THE SERUM CONCENTRATIONS OF THYROTROPHIN (TSH) AND THYROID HORMONES IN THE RAT. European Journal of Endocrinology, 1979, 91, 271-281.	3.7	37
79	l-Arginine abolishes the anxiolytic-like effect of diazepam in the elevated plus-maze test in rats. European Journal of Pharmacology, 1998, 351, 287-290.	3.5	37
80	Degradation of coeliac disease-inducing rye secalin by germinating cereal enzymes: diminishing toxic effects in intestinal epithelial cells. Clinical and Experimental Immunology, 2010, 161, 242-249.	2.6	37
81	Distribution of Prolyl Oligopeptidase in Human Peripheral Tissues and in Ovarian and Colorectal Tumors. Journal of Histochemistry and Cytochemistry, 2012, 60, 706-715.	2.5	37
82	Somatostatin, neuropeptide Y, GABA and cholinergic enzymes in brain of pentylenetetrazol-kindled rats. Neuropeptides, 1989, 14, 197-207.	2.2	36
83	Dicarboxylic Acidbis(l-Prolyl-pyrrolidine) Amides as Prolyl Oligopeptidase Inhibitors. Journal of Medicinal Chemistry, 2002, 45, 4581-4584.	6.4	36
84	4-Phenylbutanoyl-2(S)-acylpyrrolidines and 4-phenylbutanoyl- l -prolyl-2(S)-acylpyrrolidines as prolyl oligopeptidase inhibitors. Bioorganic and Medicinal Chemistry, 2002, 10, 2199-2206.	3.0	36
85	Expression and traffic of cellular prolyl oligopeptidase are regulated during cerebellar granule cell differentiation, maturation, and aging. Neuroscience, 2008, 156, 580-585.	2.3	36
86	EVIDENCE FOR DOPAMINERGIC CONTROL OF THYROTROPHIN SECRETION IN THE RAT. Journal of Endocrinology, 1977, 72, 329-335.	2.6	35
87	Clinical Potential of Catechol-O-Methyltransferase (COMT) Inhibitors as Adjuvants in ParkinsonÊ¼s Disease. CNS Drugs, 1994, 1, 172-179.	5.9	35
88	Beneficial Effect of Prolyl Oligopeptidase Inhibition on Spatial Memory in Young but Not in Old Scopolamine-Treated Rats. Basic and Clinical Pharmacology and Toxicology, 2006, 100, 061214140717002-???.	2.5	35
89	Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons. Experimental Neurology, 2009, 219, 499-506.	4.1	35
90	Receptor binding profile and anxiolytic-type activity of deramciclane (EGIS-3886) in animal models. Drug Development Research, 1997, 40, 333-348.	2.9	34

#	Article	IF	Citations
91	The use of low-molecular-weight PEIs as gene carriers in the monkey fibroblastoma and rabbit smooth muscle cell cultures. Journal of Gene Medicine, 2002, 4, 205-214.	2.8	34
92	Deramciclane, a putative anxiolytic drug, is a serotonin 5-HT 2C receptor inverse agonist but fails to induce 5-HT 2C receptor down-regulation. Psychopharmacology, 1998, 136, 99-104.	3.1	33
93	Synthesis and in Vitro Pharmacology of a Series of New Chiral Histamine H3-Receptor Ligands:â€‰ 2-(R and) Tj ETQq1 1 0.784314 rg BT 1193-1202.	6.4	33
94	Resistance to salt-induced hypertension in catechol-O-methyltransferase-gene-disrupted mice. Journal of Hypertension, 2003, 21, 2365-2374.	0.5	33
95	Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations. Journal of Psychiatry and Neuroscience, 2000, 25, 33-42.	2.4	33
96	Social isolation of rats increases the density of cholecystokinin receptors in the frontal cortex and abolishes the anti-exploratory effect of caerulein. Naunyn-Schmiedeberg's Archives of Pharmacology, 1993, 348, 96-101.	3.0	32
97	Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats. European Journal of Pharmacology, 1993, 250, 77-84.	3.5	32
98	A prolyl oligopeptidase inhibitor, Z-Pro-Prolinal, inhibits glyceraldehyde-3-phosphate dehydrogenase translocation and production of reactive oxygen species in CV1-P cells exposed to 6-hydroxydopamine. Toxicology in Vitro, 2006, 20, 1446-1454.	2.4	32
99	Vascular endothelial growth factor C acts as a neurotrophic factor for dopamine neurons in vitro and in vivo. Neuroscience, 2011, 192, 550-563.	2.3	32
100	Pharmacokinetic Studies with Trimethoprim and Different Doses of Sulfadiazine in Healthy Human Subjects. Chemotherapy, 1973, 19, 289-298.	1.6	31
101	Catecholamine metabolism in the brain by membrane-bound and soluble catechol-o-methyltransferase (COMT) estimated by enzyme kinetic values. Medical Hypotheses, 2001, 57, 628-632.	1.5	31
102	Tissue histopathology, clinical chemistry and behaviour of adultcomt-gene-disrupted mice. Journal of Applied Toxicology, 2003, 23, 213-219.	2.8	31
103	The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa. Acta Neurologica Scandinavica, 1985, 72, 385-391.	2.1	31
104	Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 1994, 349, 478-484.	3.0	30
105	Role of N-methyl-d-aspartic acid and cholecystokinin receptors in apomorphine-induced aggressive behaviour in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 1995, 351, 363-70.	3.0	30
106	No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: a microdialysis study in anaesthetized rats. European Journal of Pharmacology, 1998, 356, 127-137.	3.5	30
107	Cholecystokinin 2 receptor-deficient mice display altered function of brain dopaminergic system. Psychopharmacology, 2001, 158, 198-204.	3.1	30
108	Modification of GABAergic Activity and Thyrotropin Secretion in Male Rats. Acta Pharmacologica Et Toxicologica, 1980, 47, 241-248.	0.0	30

#	Article	IF	Citations
109	Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl- and N,N-dialkyl-carbamate esters of entacapone. Life Sciences, 2000, 67, 205-216.	4.3	29
110	Effect of S-COMT deficiency on behavior and extracellular brain dopamine concentrations in mice. Psychopharmacology, 2010, 211, 389-401.	3.1	29
111	Pain Relief and Sputum Prostaglandins in Adults Treated with Pethidine, Tilidine and Indomethacin After Tonsillectomy: A Doubleâ€Blind Study. Acta Anaesthesiologica Scandinavica, 1980, 24, 79-85.	1.6	28
112	Effects of selective catechol-O-methyltransferase inhibitors on single-trial passive avoidance retention in male rats. Behavioural Brain Research, 1997, 86, 49-57.	2.2	28
113	Brain prolyl oligopeptidase activity is associated with neuronal damage rather than Î²-amyloid accumulation. NeuroReport, 2001, 12, 3309-3312.	1.2	28
114	Atipamezole, an Î±2-adrenoceptor antagonist, augments the effects of l-DOPA on evoked dopamine release in rat striatum. European Journal of Pharmacology, 2003, 462, 83-89.	3.5	28
115	Characterization of membraneâ€bound prolyl endopeptidase from brain. FEBS Journal, 2008, 275, 4415-4427.	4.7	28
116	Biochemistry and Pharmacology of Catechol-O-Methyltransferase Inhibitors. International Review of Neurobiology, 2010, 95, 73-118.	2.0	28
117	COMT gene locus. Pain, 2015, 156, 2072-2083.	4.2	28
118	Plasma Renin Activity and in vitro Synthesis of Aldosterone by the Adrenal Glands of Rats with Spontaneous, Renal, or Pinealectomyâ€Induced Hypertension. Acta Physiologica Scandinavica, 1975, 94, 184-188.	2.2	27
119	Combination of CDNF and Deep Brain Stimulation Decreases Neurological Deficits in Late-stage Model Parkinsonâ€™s Disease. Neuroscience, 2018, 374, 250-263.	2.3	27
120	Diurnal variations of medial basal and anterior hypothalamic thyroliberin [TRH] and serum thyrotropin [TSH] concentrations in male rats. Life Sciences, 1978, 23, 1343-1349.	4.3	26
121	Microdialysis Studies on the Action of Tolcapone on Pharmacologicallyâ€Elevated Extracellular Dopamine Levels in Conscious Rats. Basic and Clinical Pharmacology and Toxicology, 1999, 85, 233-238.	0.0	26
122	Effects of histamine H3-ligands on the levodopa-induced turning behavior of hemiparkinsonian rats. Parkinsonism and Related Disorders, 2000, 6, 159-164.	2.2	26
123	Quantitation of entacapone glucuronide in rat plasma by on-line coupled restricted access media column and liquid chromatographyâ€“tandem mass spectrometry. Biomedical Applications, 2001, 759, 227-236.	1.7	26
124	The role of PEI structure and size in the PEI/liposome-mediated synergism of gene transfection. Plasmid, 2009, 61, 15-21.	1.4	26
125	Comparison of two new inhibitors of catechol Oâ€methylation on striatal dopamine metabolism: a microdialysis study in rats. British Journal of Pharmacology, 1994, 112, 13-18.	5.4	25
126	High correlation between in vivo [123I]Î²-CIT SPECT/CT imaging and post-mortem immunohistochemical findings in the evaluation of lesions induced by 6-OHDA in rats. EJNMMI Research, 2013, 3, 46.	2.5	25

#	Article	IF	Citations
127	Deficiency of prolyl oligopeptidase in mice disturbs synaptic plasticity and reduces anxiety-like behaviour, body weight, and brain volume. European Neuropsychopharmacology, 2016, 26, 1048-1061.	0.7	25
128	NEUROTRANSMISSION AND SECRETION OF THYROID-STIMULATING HORMONE. Lancet, The, 1973, 302, 510-511.	13.7	24
129	Possible involvement of nigrostriatal dopamine system in the inhibition of thyrotropin secretion in the rat. European Journal of Pharmacology, 1981, 76, 403-409.	3.5	24
130	Effect of acute levodopa on brain catecholamines after selective MAO and COMT inhibition in male rats. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1990, 2, 31-43.	1.2	24
131	Spatial association of prolyl oligopeptidase, inositol 1,4,5-triphosphate type 1 receptor, substance P and its neurokinin-1 receptor in the rat brain: An immunohistochemical colocalization study. Neuroscience, 2008, 153, 1177-1189.	2.3	24
132	Combination of snap freezing, differential pH two-dimensional reverse-phase high-performance liquid chromatography, and iTRAQ technology for the peptidomic analysis of the effect of prolyl oligopeptidase inhibition in the rat brain. Analytical Biochemistry, 2009, 393, 80-87.	2.4	24
133	Concentrations of metronidazole and tinidazole in male genital tissues. Antimicrobial Agents and Chemotherapy, 1985, 28, 812-814.	3.2	23
134	Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat. Naunyn-Schmiedeberg's Archives of Pharmacology, 1991, 344, 412-8.	3.0	23
135	Validation of assay of catechol-O-methyltransferase activity in human erythrocytes. Journal of Pharmaceutical and Biomedical Analysis, 1996, 14, 515-523.	2.8	23
136	Conformationally rigid N-acyl-5-alkyl-l-prolyl-pyrrolidines as prolyl oligopeptidase inhibitors. Bioorganic and Medicinal Chemistry, 2003, 11, 3611-3619.	3.0	23
137	Complex estrogenic regulation of catechol-O-methyltransferase (COMT) in rats. Journal of Physiology and Pharmacology, 2011, 62, 483-90.	1.1	23
138	Absorption of erythromycin acistrate and erythromycin base in the fasting and non-fasting state. Journal of Antimicrobial Chemotherapy, 1988, 21, 45-55.	3.0	22
139	Effects of aqueous solubility and dissolution characteristics on oral bioavailability of entacapone. Drug Development Research, 2000, 49, 238-244.	2.9	22
140	Stressâ€induced Analgesia and Morphine Responses Are Changed in Catecholâ€Oâ€methyltransferaseâ€Deficient Male Mice. Basic and Clinical Pharmacology and Toxicology, 2008, 103, 367-373.	2.5	22
141	Different viabilities and toxicity types after 6-OHDA and Ara-C exposure evaluated by four assays in five cell lines. Toxicology in Vitro, 2008, 22, 182-189.	2.4	22
142	Distribution and Functions of Catechol-O-Methyltransferase Proteins. International Review of Neurobiology, 2010, 95, 29-47.	2.0	22
143	Copy number elevation of 22q11.2 genes arrests the developmental maturation of working memory capacity and adult hippocampal neurogenesis. Molecular Psychiatry, 2018, 23, 985-992.	7.9	22
144	Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and l-dihydroxyphenylalanine in rat models of depression. European Journal of Pharmacology, 1995, 274, 229-233.	3.5	21

#	Article	IF	Citations
145	The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration. European Journal of Pharmaceutical Sciences, 2005, 24, 503-511.	4.0	21
146	Deficient activity of mammalian prolyl oligopeptidase on the immunoactive peptide digestion in coeliac disease. Scandinavian Journal of Gastroenterology, 2007, 42, 562-571.	1.5	21
147	Importance of membraneâ€bound catecholâ€Oâ€methyltransferase in Lâ€DOPA metabolism: a pharmacokinetic study in two types of Comt gene modified mice. British Journal of Pharmacology, 2009, 158, 1884-1894.	5.4	21
148	Minocycline protects SHâ€SY5Y cells from 6â€hydroxydopamine by inhibiting both caspaseâ€dependent and â€independent programmed cell death. Journal of Neuroscience Research, 2012, 90, 682-690.	2.9	21
149	Pharrnacokinetics of nalidixinic acid and oxolinic acid in healthy wornen. Clinical Pharmacology and Therapeutics, 1976, 19, 37-46.	4.7	20
150	Absorption of rifampin from various preparations and pharmaceutic forms. Clinical Pharmacology and Therapeutics, 1977, 21, 370-374.	4.7	20
151	Effect of stress and dexamethasone on immunoreactive Î²â€endorphin levels in rat hypothalamus and pineal. Acta Physiologica Scandinavica, 1982, 114, 537-541.	2.2	20
152	Pharmacokinetics of slow-release diltiazem and its effect on atrioventricular conduction in healthy volunteers. European Journal of Clinical Pharmacology, 1986, 31, 423-426.	1.9	20
153	The roles of dopamine transporter and Bcl-2 protein in the protection of CV1-P cells from 6-OHDA-induced toxicity. Toxicology Letters, 2004, 154, 117-123.	0.8	20
154	Slow-binding inhibitors of prolyl oligopeptidase with different functional groups at the P1 site. Biochemical Journal, 2004, 382, 1003-1008.	3.7	20
155	Four day inhibition of prolyl oligopeptidase causes significant changes in the peptidome of rat brain, liver and kidney. Biochimie, 2012, 94, 1849-1859.	2.6	20
156	Alteration of prolyl oligopeptidase and activated Î±-2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome. Biochemical Pharmacology, 2013, 85, 1783-1794.	4.4	20
157	Anesthetics and Thyrotropin Secretion in the Rat. Endocrinology, 1976, 99, 875-880.	2.8	19
158	Pharmacokinetics of methenamine in healthy volunteers. Journal of Antimicrobial Chemotherapy, 1982, 9, 209-216.	3.0	19
159	Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. European Journal of Clinical Pharmacology, 1983, 24, 227-230.	1.9	19
160	Concentrations of metronidazole and tinidazole in female reproductive organs after a single intravenous infusion and after repeated oral administration. Infection, 1984, 12, 197-201.	4.7	19
161	Tonsillar penetration of erythromycin and its 2'-acetyl ester in patients with chronic tonsillitis. Journal of Antimicrobial Chemotherapy, 1988, 21, 73-84.	3.0	19
162	Acute Toxicity of Three New Selective COMT Inhibitors in Mice with Special Emphasis on Interactions with Drugs Increasing Catecholaminergic Neurotransmission. Basic and Clinical Pharmacology and Toxicology, 1991, 69, 64-70.	0.0	19

#	Article	IF	Citations
163	Increase of catechol-O-methyltransferase activity in rat brain microglia after intrastriatal infusion of fluorocitrate, a glial toxin. Neuroscience Letters, 1997, 230, 155-158.	2.1	19
164	Apomorphine-induced behavioural sensitization in rats: individual differences, role of dopamine and NMDA receptors. European Neuropsychopharmacology, 1999, 9, 507-514.	0.7	19
165	Entacapone protects from angiotensin II-induced inflammation and renal injury. Journal of Hypertension, 2003, 21, 2353-2363.	0.5	19
166	Dual action of morphine on cold-stimulated thyrotropin secretion in male rats. Life Sciences, 1984, 35, 1101-1107.	4.3	18
167	Relation of exploratory behavior of rats in elevated plus-maze to brain receptor binding properties and serum growth hormone levels. European Neuropsychopharmacology, 1997, 7, 289-294.	0.7	18
168	Different renal effects of two inhibitors of catecholâ€Oâ€methylation in the rat: Entacapone and CGP 28014. Acta Physiologica Scandinavica, 1998, 162, 489-494.	2.2	18
169	Increase in Free Choice Oral Ethanol Selfâ€Administration in Catecholâ€Oâ€Methyltransferase Geneâ€Disrupted Male Mice. Basic and Clinical Pharmacology and Toxicology, 2008, 103, 297-304.	2.5	18
170	Sex-dependent compensated oxidative stress in the mouse liver upon deletion of catechol O-methyltransferase. Biochemical Pharmacology, 2009, 77, 1541-1552.	4.4	18
171	Constitutive Ret signaling is protective for dopaminergic cell bodies but not for axonal terminals. Neurobiology of Aging, 2011, 32, 1486-1494.	3.1	18
172	NEUROTRANSMITTER CONTROL OF THYROTROPHIN SECRETION IN HYPOTHYROID RATS. European Journal of Endocrinology, 1978, 89, 100-107.	3.7	17
173	Inhibition of the TSH secretion by histamine in male rats. European Journal of Endocrinology, 1983, 103, 88-94.	3.7	17
174	Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers. Antimicrobial Agents and Chemotherapy, 1984, 26, 69-73.	3.2	17
175	Skin irritation by dithranol (anthralin) and its 10-acyl analogues in 3 animal models. Contact Dermatitis, 1984, 10, 140-145.	1.4	17
176	Potentiation of central effects of L-dopa by an inhibitor of catechol-O-methyltransferase. Journal of Neural Transmission, 1987, 70, 233-240.	2.8	17
177	Minor Effect of Tolcapone, a Catecholâ€Oâ€Methyltransferase Inhibitor, on Extracellular Dopamine Levels Modified by Amphetamine or Pargyline: A Microdialysis Study in Anaesthetized Rats. Basic and Clinical Pharmacology and Toxicology, 1996, 78, 392-396.	0.0	17
178	New Prolyl Oligopeptidase Inhibitors Developed from Dicarboxylic Acid Bis(l-prolyl-pyrrolidine) Amides. Journal of Medicinal Chemistry, 2003, 46, 4543-4551.	6.4	17
179	Ara-C induces apoptosis in monkey fibroblast cells. Toxicology in Vitro, 2003, 17, 367-373.	2.4	17
180	2(S)-(Cycloalk-1-enecarbonyl)-1-(4-phenyl-butanoyl)pyrrolidines and 2(S)-(aroyl)-1-(4-phenylbutanoyl)pyrrolidines as prolyl oligopeptidase inhibitors. Bioorganic and Medicinal Chemistry, 2007, 15, 2024-2031.	3.0	17

#	Article	IF	Citations
181	Intracerebroventricular antisense knockdown of GÎ±i2 results in ciliary stasis and ventricular dilatation in the rat. BMC Neuroscience, 2007, 8, 26.	1.9	17
182	Inhibitors of catecholâ€Oâ€methyltransferase sensitize mice to pain. British Journal of Pharmacology, 2010, 161, 1553-1565.	5.4	17
183	DUAL ACTION OF ADRENERGIC SYSTEM ON THE REGULATION OF THYROTROPHIN SECRETION IN THE MALE RAT. European Journal of Endocrinology, 1979, 90, 249-258.	3.7	16
184	Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase. European Journal of Pharmacology, 1993, 239, 39-45.	3.5	16
185	N-Nitro-L-arginine attenuates development of tolerance to antinociceptive but not to hormonal effects of morphine. European Journal of Pharmacology, 1994, 259, 57-64.	3.5	16
186	Opioid antagonist naloxone potentiates anxiogenic-like action of cholecystokinin agonists in elevated plus-maze. Neuropeptides, 1998, 32, 235-240.	2.2	16
187	Complex Role of 5-HT in the Regulation of TSH Secretion in the Male Rat. Hormone Research, 1981, 14, 165-179.	1.8	15
188	Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion. Journal of Antimicrobial Chemotherapy, 1982, 9, 461-470.	3.0	15
189	Studies on the site and mechanism of the inhibitory action of intracerebral histamine on the cold-stimulated thyrotropin secretion in male rats. Brain Research, 1985, 343, 329-335.	2.2	15
190	Effects of central and peripheral type benzodiazepine ligands on thyrotropin and prolactin secretion. Neuropeptides, 1992, 21, 183-191.	2.2	15
191	Catechol O-Methyltransferase: Characterization of the Protein, Its Gene, and the Preclinical Pharmacology of COMT Inhibitors. Advances in Pharmacology, 1997, 42, 324-328.	2.0	15
192	Pharmacokinetics of Clofibrate and Chlorophenoxy Isobutyric Acid. I. Cross-over Studies on Human Volunteers. Acta Pharmacologica Et Toxicologica, 2009, 36, 353-365.	0.0	15
193	Different Effects of Scopolamine and Inhibition of Prolyl Oligopeptidase on Mnemonic and Motility Functions of Young and 8â€to 9â€Monthâ€Old Rats in the Radialâ€Arm Maze. Basic and Clinical Pharmacology and Toxicology, 2010, 106, 280-287.	2.5	15
194	Catechol-O-Methyltransferase (COMT) Protein Expression and Activity after Dopaminergic and Noradrenergic Lesions of the Rat Brain. PLoS ONE, 2013, 8, e61392.	2.5	15
195	Tumor-producing and skin-irritating activity of dithranol (anthralin) and its 10-acyl analogues in SENCAR mice. Carcinogenesis, 1986, 7, 1755-1760.	2.8	14
196	Possible role of cholecystokinin-A receptors in regulation of thyrotropin (TSH) secretion in male rats. Neuropeptides, 1992, 23, 251-258.	2.2	14
197	An acute i.c.v. infusion of leptin has no effect on hypothalamic histamine and tele-methylhistamine contents in Wistar rats. European Journal of Pharmacology, 2000, 395, 113-119.	3.5	14
198	Failure of FK506 (tacrolimus) to alleviate apomorphine-induced circling in rat Parkinson model in spite of some cytoprotective effects in SH-SY5Y dopaminergic cells. Brain Research, 2005, 1038, 83-91.	2.2	14

#	Article	IF	Citations
199	Dicarboxylic Acid Azacyclel-Prolyl-pyrrolidine Amides as Prolyl Oligopeptidase Inhibitors and Three-Dimensional Quantitative Structureâ^'Activity Relationship of the Enzymeâ^'Inhibitor Interactions. Journal of Medicinal Chemistry, 2005, 48, 4772-4782.	6.4	14
200	Pharmacokinetics of sustained-release verapamil after a single administration and at steady state. European Journal of Drug Metabolism and Pharmacokinetics, 1985, 10, 133-138.	1.6	13
201	Tolcapone, an inhibitor of catechol: O-methyltransferase, counteracts memory deficits caused by bilateral cholinotoxin lesions of the basal nuclei of Meynert. NeuroReport, 1995, 6, 1219-1222.	1.2	13
202	Reduced natriuretic response to acute sodium loading in COMT gene deleted mice. BMC Physiology, 2002, 2, 14.	3.6	13
203	Central regulation of thyrotropin secretion in rats: methodological aspects, problems and some progress. Medical Biology, 1983, 61, 92-100.	0.4	13
204	Effects of systemic carbidopa on dopamine synthesis in rat hypothalamus and striatum. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1992, 4, 143-154.	1.2	12
205	Effects of bilateral cholinotoxin infusions on the behavior and brain biochemistry of the rats. Pharmacology Biochemistry and Behavior, 1994, 49, 33-40.	2.9	12
206	Differential disappearance of tolerance to thermal, hormonal and locomotor effects of morphine in the male rat. European Journal of Pharmacology, 1995, 285, 69-77.	3.5	12
207	The role of dopamine-metabolizing enzymes in the regulation of renal sodium excretion in the rat. Pflugers Archiv European Journal of Physiology, 2001, 442, 505-510.	2.8	12
208	Sequential Expression, Activity and Nuclear Localization of Prolyl Oligopeptidase Protein in the Developing Rat Brain. Developmental Neuroscience, 2011, 33, 38-47.	2.0	12
209	Effect of Genetic Modifications in the Synaptic Dopamine Clearance Systems on Addiction-like Behaviour in Mice. Basic and Clinical Pharmacology and Toxicology, 2011, 108, 2-8.	2.5	12
210	Hunting for Peptide Substrates of Prolyl Oligopeptidase: Classical Versus Non-Classical Bioactive Peptides. CNS and Neurological Disorders - Drug Targets, 2011, 10, 319-326.	1.4	12
211	Further evidence of the dual role of noradrenaline in regulation of thyrotrophin secretion in male rats. European Journal of Endocrinology, 1981, 97, 213-220.	3.7	11
212	Toxicological studies with dithranol and its 10-acyl analogues. Archives of Toxicology, 1986, 59, 180-185.	4.2	11
213	Concentrations of erythromycin, 2'-acetyl erythromycin, and their anhydro forms in plasma and tonsillar tissue after repeated dosage of erythromycin stearate and erythromycin acistrate. Antimicrobial Agents and Chemotherapy, 1988, 32, 1019-1024.	3.2	11
214	Lack of increased oxidative stress in catechol-O-methyltransferase (COMT)-deficient mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 370, 279-289.	3.0	11
215	Effect of forced chronic oral nicotine exposure on intravenous self-administration and rewarding properties of acute nicotine. European Journal of Pharmacology, 2008, 591, 164-170.	3.5	11
216	Different Interactions of Prolyl Oligopeptidase and Neurotensin in Dopaminergic Function of the Rat Nigrostriatal and Mesolimbic Pathways. Neurochemical Research, 2012, 37, 2033-2041.	3.3	11

#	Article	IF	Citations
217	Comparison of motor performance, brain biochemistry and histology of two A30P Î±-synuclein transgenic mouse strains. Neuroscience, 2013, 231, 157-168.	2.3	11
218	Effect of chronic morphine treatment on thyrotropin and prolactin levels and acute hormone responses in the rat. Journal of Pharmacology and Experimental Therapeutics, 1988, 246, 649-54.	2.5	11
219	Studies with lithium in euthyrotic, hyperthyrotic and hypothyrotic rats. Life Sciences, 1971, 10, 9-19.	4.3	10
220	AMINE UPTAKE AND THYROTROPIN-RELEASING HORMONE. Lancet, The, 1973, 301, 836.	13.7	10
221	Further Studies of Serotonergic Activity in the Regulation of the Cold Stimulated Thyrotropin Secretion in Male Rats. Basic and Clinical Pharmacology and Toxicology, 1988, 63, 65-69.	0.0	10
222	Efficient Transfection of Novel Bovine Papillomavirus 1 Expression Plasmids. Plasmid, 2001, 46, 163-169.	1.4	10
223	Effect of cell-surface glycosaminoglycans on cationic carrier combined with low-MW PEI-mediated gene transfection. International Journal of Pharmaceutics, 2004, 284, 43-52.	5.2	10
224	Synthesis and Characterization of the Novel Fluorescent Prolyl Oligopeptidase Inhibitor 4-Fluoresceinthiocarbamoyl- 6-aminocaproyl-l-prolyl-2(S)-(Hydroxy- acetyl)pyrrolidine. Journal of Medicinal Chemistry, 2005, 48, 7093-7095.	6.4	10
225	Concentrations of Tinidazole in Breast Milk. Acta Pharmacologica Et Toxicologica, 1983, 53, 254-256.	0.0	10
226	Molecular dynamics study of prolyl oligopeptidase with inhibitor in binding cavity. SAR and QSAR in Environmental Research, 2009, 20, 595-609.	2.2	10
227	Cross-over study of ten tetracycline preparations. European Journal of Clinical Pharmacology, 1973, 6, 64-68.	1.9	9
228	Further studies on properties of renin granules isolated from rat kidney cortex. Acta Physiologica Scandinavica, 1981, 112, 365-371.	2.2	9
229	Effect of nitecapone and clorgyline, given intracerebro-ventricularly on L-dopa metabolism in the rat brain. NeuroReport, 1992, 3, 641-644.	1.2	9
230	Î¼- and Î´-opioid receptor antisense oligodeoxynucleotides antagonize morphine-induced growth hormone secretion in rats. European Journal of Pharmacology, 1995, 284, 227-230.	3.5	9
231	Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats. Journal of Neuroscience Methods, 2001, 109, 47-52.	2.5	9
232	Brain histamine and histamine H3 receptors following repeated l-histidine administration in rats. Life Sciences, 2003, 73, 1491-1503.	4.3	9
233	An introduction of a pyridine group into the structure of prolyl oligopeptidase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5590-5593.	2.2	9
234	Comparison of the Effects of Deramciclane, Ritanserin and Buspirone on Extracellular Dopamine and Its Metabolites in Striatum and Nucleus Accumbens of Freely Moving Rats. Basic and Clinical Pharmacology and Toxicology, 2007, 102, 071027162142001-???.	2.5	9

#	Article	IF	Citations
235	Serotonergic Activation after 2-Week Intrastriatal Infusion of l-Dopa and Slow Recovery of Circling in Rats with Unilateral Nigral Lesions. Basic and Clinical Pharmacology and Toxicology, 2008, 102, 300-307.	2.5	9
236	Localization of prolyl oligopeptidase in the thalamic and cortical projection neurons: A retrograde neurotracing study in the rat brain. Neuroscience Letters, 2009, 450, 201-205.	2.1	9
237	Nitecapone reduces development and symptoms of neuropathic pain after spinal nerve ligation in rats¹. European Journal of Pain, 2011, 15, 732-740.	2.8	9
238	Pharmacokinetics of pipemidic` acid in healthy middle-aged volunteers and elderly patients with renal insufficiency. Xenobiotica, 1984, 14, 339-347.	1.1	8
239	Site-Dependent Action of Intracerebroventricular 5-Hydroxytryptamine on the Cold-Stimulated Thyrotropin Secretion in Male Rats. Neuroendocrinology, 1990, 51, 45-50.	2.5	8
240	Selective cardiorespiratory activity of an iodinated analog of thyrotropin-releasing hormone (TRH). Peptides, 1990, 11, 939-944.	2.4	8
241	Complex actions of serotonergic agonists on cold-stimulated TSH secretion in male rats. European Journal of Pharmacology, 1990, 180, 91-102.	3.5	8
242	Subdiaphragmatic vagotomy does not prevent the anti-exploratory effect of caerulein in the elevated plus-maze. Neuropeptides, 1994, 26, 39-45.	2.2	8
243	Morphine Withdrawal Alters Anterior Pituitary Hormone Secretion, Brain Endopeptidase Activity and Brain Monoamine Metabolism in the Rat. Basic and Clinical Pharmacology and Toxicology, 1996, 78, 129-135.	0.0	8
244	Increased p53 levels without caspase-3 activity and change of cell viability in 6-hydroxydopamine-treated CV1-P cells. Cell Biology and Toxicology, 2003, 19, 177-187.	5.3	8
245	Generation of membrane-bound catechol-O-methyl transferase deficient mice with disctinct sex dependent behavioral phenotype. Journal of Physiology and Pharmacology, 2016, 67, 827-842.	1.1	8
246			

#	Article	IF	Citations
253	Lack of Effect of Leptin on the Behaviour of Mice Predicting the Level of Anxiety and Depression. Basic and Clinical Pharmacology and Toxicology, 1998, 83, 139-142.	0.0	7
254	Hypothalamic histamine, growth rate, plasma prolactin and growth hormone levels in rats with long-term portacaval anastomosis. Inflammation Research, 1999, 48, 81-85.	4.0	7
255	Elimination of extracellular dopamine in the medial prefrontal cortex of conscious mice analysed using selective enzyme and uptake inhibitors. Journal of Physiology and Pharmacology, 2016, 67, 301-9.	1.1	7
256	A 6-month dermal toxicity test with dithranol and butantrone in miniature swine. Contact Dermatitis, 1986, 15, 1-9.	1.4	6
257	Effects of hypothalamic paraventricular nucleus lesion on the coldâ€stimulated TSH responses to 5â€HT in male rats. Acta Physiologica Scandinavica, 1990, 139, 233-240.	2.2	6
258	Variation in tolerance to the antinociceptive, hormonal and thermal effects of morphine after a 5-day pre-treatment of male rats with increasing doses of morphine. Naunyn-Schmiedeberg's Archives of Pharmacology, 1994, 349, 161-9.	3.0	6
259	Association of Prolyl Oligopeptidase with Conventional Neurotransmitters in the Brain. CNS and Neurological Disorders - Drug Targets, 2011, 10, 311-318.	1.4	6
260	Unpredictable Rotational Responses to Lâ€dopa in the Rat Model of Parkinsonâ€™s Disease: the Role of Lâ€dopa Pharmacokinetics and Striatal Dopamine Depletion. Basic and Clinical Pharmacology and Toxicology, 2012, 110, 162-170.	2.5	6
261	Neurochemical and psychomotor interactions of new selective COMT inhibitors with clorgyline and nomifensine in levodopa-treated rats and mice. Archives Internationales De Pharmacodynamie Et De ThÃ©rapie, 1992, 320, 5-20.	0.2	6
262	Differential effect of tetracaine and bupivacaine on catecholamine and 5-hydroxytryptamine turnover. Pain, 1987, 29, 239-245.	4.2	5
263	Central and peripheral type benzodiazepine ligands displace [3H][3-Me-His2]TRH from its binding sites in the brain and the anterior pituitary and antagonize the effect of TRH in the rat duodenum. Neuropeptides, 1991, 19, 147-155.	2.2	5
264	Opposite Effect of Ethanol on Recombinant Membraneâ€Bound and Soluble Activities of Catecholâ€Oâ€methyltransferase. Basic and Clinical Pharmacology and Toxicology, 1995, 77, 414-416.	0.0	5
265	CATECHOL 0-METHYLTRANSFERASE. , 1999, , 55-91.		5
266	Effect of modified brain histamine contents on prolactin and thyrotropin secretion in male rats. European Journal of Endocrinology, 1996, 134, 209-214.	3.7	5
267	Tumor-producing activity of dithranol (anthralin) and two of its 10-acyl analogs in the dorsal skin of female NMRI mice. Journal of Pharmacology and Experimental Therapeutics, 1984, 229, 255-60.	2.5	5
268	Effects of acute hypotension and hypertension on serum TSH concentrations in male rats. Acta Physiologica Scandinavica, 1979, 107, 105-107.	2.2	4
269	Studies on the Role of the Pineal Gland in the Regulation of TSH Secretion in Postpuberal Male Rats. Hormone Research, 1981, 14, 24-35.	1.8	4
270	Nitrofurantoin is highly bound to plasma protein. Journal of Antimicrobial Chemotherapy, 1982, 9, 327-328.	3.0	4

#	Article	IF	Citations
271	Studies on the mechanism of the enhanced cold-induced TSH secretion in spontaneously hypertensive rats. Experientia, 1983, 39, 423-424.	1.2	4
272	Effect of Erythromycin Acistrate and Erythromycin Stearate on Human Colonic Microflora. Scandinavian Journal of Infectious Diseases, 1989, 21, 717-720.	1.5	4
273	Development of tolerance to the hormonal effects of morphine without changes in the aminergic functions in the brain of the rat. Neuropharmacology, 1992, 31, 765-770.	4.1	4
274	Hormone responses to sedative drugs and cold exposure in two rat lines with high and low alcohol sensitivity. Pharmacology Biochemistry and Behavior, 1992, 41, 795-799.	2.9	4
275	Biogenic amine metabolites in the CSF of patients with late onset and alcoholic ataxias. Acta Neurologica Scandinavica, 1993, 87, 309-311.	2.1	4
276	Evidence for cholecystokininA receptors in bovine adrenal chromaffin cells. NeuroReport, 1996, 7, 2167-2170.	1.2	4
277	Production of functional recombinant tyrosine hydroxylase by the BPV-1 expression plasmids in the cell cultures. Plasmid, 2003, 50, 230-235.	1.4	4
278	Synthesis and in-vitro/in-vivo evaluation of orally administered entacapone prodrugs. Journal of Pharmacy and Pharmacology, 2010, 53, 1489-1498.	2.4	4
279	Effects of Diverse Psychopharmacological Substances on the Activity of Brain Prolyl Oligopeptidase. Basic and Clinical Pharmacology and Toxicology, 2011, 108, 46-54.	2.5	4
280	A Transient Inhibition and Permanent Lack of Catecholâ€‹Oâ€‹Methyltransferase have Minor Effects on Feeding Pattern of Female Rodents. Basic and Clinical Pharmacology and Toxicology, 2012, 110, 307-313.	2.5	4
281	Subacute administration of both methcathinone and manganese causes basal ganglia damage in mice resembling that in methcathinone abusers. Journal of Neural Transmission, 2020, 127, 707-714.	2.8	4
282	Aminergic regulation of neuroendocrinological functions: theoretical background and some clinical examples. Medical Biology, 1987, 65, 121-6.	0.4	4
283	Isolation of Renin Granules from Rat Kidney Cortex by Isotonic or Hyperosmotic Metrizamide-Sucrose Gradients. Preparative Biochemistry and Biotechnology, 1980, 10, 297-316.	0.5	3
284	Determination of a novel antitussive agent 2â€²,4â€²-dimethyl-6â€²-methoxy-3-(2-methylpiperidyl)-propionaldehyde in plasma by high-performance liquid chromatography. Biomedical Applications, 1983, 278, 225-227.	1.7	3
285	On-line radiochemical assay for monoamine oxidase utilizing high-performance liquid chromatography. Journal of Pharmacological Methods, 1984, 12, 247-254.	0.7	3
286	Effect of Enzyme Induction and Inhibition on the Fate of Metronidazole and Tinidazole in the Rat. Basic and Clinical Pharmacology and Toxicology, 1987, 60, 24-28.	0.0	3
287	Amiridine (NIK-247) and cerebrocrast in the alleviation of cholinergic lesion-induced learning deficit in male rats. Drug Development Research, 1993, 30, 219-228.	2.9	3
288	Cold exposure attenuates effects of secretagogues on serum prolactin and growth hormone levels in male rats. American Journal of Physiology - Endocrinology and Metabolism, 1995, 268, E758-E765.	3.5	3

#	Article	IF	Citations
289	Nitric oxide mediates caeruleininduced suppression of locomotor activity. Neuropeptides, 1996, 30, 323-326.	2.2	3
290	Neuroendocrine Effects of Dexmedetomidine: Evidence of Crossâ€Tolerance Between a Î¼â€Opioid Agonist and an Î±₂â€Adrenoceptor Agonist in Growth Hormone Secretion of the Male Rat. Basic and Clinical Pharmacology and Toxicology, 1996, 78, 136-142.	0.0	3
291	Histamine H 3 receptor binding sites in rat cortex following L-histidine loading. Inflammation Research, 1999, 48, 59-60.	4.0	3
292	Pharmacodynamic Response of Entacapone in Rats after Administration of Entacapone Formulations and Prodrugs with Varying Bioavailabilities. Basic and Clinical Pharmacology and Toxicology, 2002, 90, 327-332.	0.0	3
293	Advanced brain dopamine transporter imaging in mice using small-animal SPECT/CT. EJNMMI Research, 2012, 2, 55.	2.5	3
294	The cold-induced TSH secretion is resistant to alterations in the physicochemical properties of the intracerebral infusions. Journal of Endocrinological Investigation, 1983, 6, 225-228.	3.3	2
295	Penetration of Trimethoprim and Sulfadiazine into Sinus Secretion in Acute Maxillary Sinusitis. Chemotherapy, 1983, 29, 174-177.	1.6	2
296	Cholinergic regulation of thyrotropin secretion in male rats. European Journal of Pharmacology, 1988, 157, 117-124.	3.5	2
297	Anterolateral Hypothalamic Deafferentation Inhibits Histamine-Induced Prolactin Secretion and Potentiates TRH-Induced Thyrotropin Secretion in Male Rats. Neuroendocrinology, 1991, 54, 274-278.	2.5	2
298	Effects of Central and Peripheral Type Benzodiazepine Ligands on Growth Hormone and Gonadotropin Secretion in Male Rats[*]. Basic and Clinical Pharmacology and Toxicology, 1992, 71, 75-80.	0.0	2
299	Optimization of the Hydrolysis of Conjugated L-DOPA, Dopamine and Dihydroxyphenylacetic Acid in Human Urine for Assay by High-Performance Liquid Chromatography with Electrochemical Detection. Clinical Chemistry and Laboratory Medicine, 1997, 35, 229-35.	2.3	2
300	Catechol-O-methyltransferase activity in rat brain primary neuronal and glial cell cultures and its inhibitation by novel drugs. Neuroscience Research Communications, 1999, 25, 71-77.	0.2	2
301	Synthesis and biological evaluation of 6/7-exo-methyl-3Î²-(4-iodo)phenyltropane-2Î²-carboxylic acid methyl esters. European Journal of Medicinal Chemistry, 2005, 40, 299-304.	5.5	2
302	Sample purification improves the analysis of nonviral in vivo gene transfection. Plasmid, 2010, 63, 27-30.	1.4	2
303	Synthesis and biological evaluation of novel 123I-labeled 4-(4-iodophenyl)butanoyl-l-prolyl-(2S)-pyrrolidines for imagingÂprolyl oligopeptidase inÂvivo. European Journal of Medicinal Chemistry, 2014, 79, 436-445.	5.5	2
304	Delayed O-methylation of l-DOPA in MB-COMT-deficient mice after oral administration of l-DOPA and carbidopa. Xenobiotica, 2018, 48, 325-331.	1.1	2
305	Hypothalamus-adenohypophysis-thyroid axis in spontaneously hypertensive rats (SHR). Experientia, 1981, 37, 907-909.	1.2	1
306	Target Tissue Morphology and Serum Biochemistry following 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) Exposure in a TCDD-Susceptible and a TCDD-Resistant Rat Strain. Toxicological Sciences, 1989, 12, 698-712.	3.1	1

#	Article	IF	Citations
307	Lighting conditions affect serum and pituitary TSH in male rats. American Journal of Physiology - Endocrinology and Metabolism, 1990, 259, E162-E169.	3.5	1
308	Effect of subchronic administration of tolcapone on L-DOPA-and carbidopa-induced release of striatal dopamine and its metabolites. Bulletin of Experimental Biology and Medicine, 1998, 125, 145-147.	0.8	1
309	Effects of Repeated Low Dose Administration and Withdrawal of Haloperidol on Sexual Behaviour of Male Rats. Basic and Clinical Pharmacology and Toxicology, 1999, 84, 292-295.	0.0	1
310	Regional distribution of histamine H3 receptor binding sites in rat brain following L-histidine loading â€" an autoradiography study. Inflammation Research, 2000, 49, 47-48.	4.0	1
311	Expression of tyrosine hydroxylase in the striatum of atipamezole-treated rats. European Journal of Pharmaceutical Sciences, 2009, 36, 602-604.	4.0	1
312	Efficacy of erythromycin acistrate (2'-acetyl erythromycin stearate) and erythromycin stearate in experimental infections in mice. Journal of Pharmacology and Experimental Therapeutics, 1989, 250, 1028-33.	2.5	1
313	Time relationships and reversal by two indoleamines of the pinealectomy-inhibited thyrotropin secretion in male rats. Medical Biology, 1987, 65, 267-72.	0.4	1
314	Ampicillin concentrations in serum and bronchial mucosa after ampicillin and bacampicillln. Journal of Antimicrobial Chemotherapy, 1979, 5, 236-238.	3.0	0
315	Effect of alcohol on the serum TSH level in rats predisposed and not predisposed to alcohol. Bulletin of Experimental Biology and Medicine, 1981, 92, 883-885.	0.8	0
316	Adrenalectomy modifies the effect of intracerebral histamine on the cold-stimulated TSH secretion in male rats. Agents and Actions, 1986, 18, 479-484.	0.7	0
317	Effects of Cysteamine Pretreatment and Hypothalamic Periventricular Nucleus Lesion on the Cold-Stimulated Thyrotropin Responses to Intracerebroventricular 5-Hydroxytryptamine in Male Rats. Journal of Neuroendocrinology, 1990, 2, 485-492.	2.6	0
318	Tolcapone. CNS Drugs, 1996, 5, 482.	5.9	0
319	L-Dopa-induced desensitization depends on 5-hydroxytryptamine imbalance in hemiparkinsonian rats. NeuroReport, 2009, 20, 313-318.	1.2	0
320	Effects of Catechol-O-Methyltransferase Deficiency on the Reinforcing Effects of Cocaine (an) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222	0.4	0
321	CNS Catecholamine Metabolism â€" Emerging Concepts. , 2014, , 67.		0
322	Animal Studies on CCK and Anxiety. Neuroscience Intelligence Unit, 1995, , 57-72.	0.5	0
323	Catechol-O-Methyltransferase. , 2021, , 414-419.		0